secwatch.observer — SEC 8-K summary
======================================

Issuer:     BIOCRYST PHARMACEUTICALS INC (BCRX)
CIK:        0000882796
Form:       8-K
Filed at:   2026-06-12T20:10:10+00:00
Accession:  0001171843-26-004096
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioCryst shareholders approve 7M share increase to Stock Incentive Plan
-----------------------------------------------------------------------

- Incentive Plan approved with 119.8M for, 63.3M against, adding 7M shares to the Plan.
- Directors Heggie, McKee, Stonehouse re-elected; each received >170M votes for.
- Non-binding say-on-pay passed but 56.8M (31% of votes cast) voted against.
- Ernst & Young ratified as 2026 auditor with 210.3M votes for, 7.2M against.
- 34.0M broker non-votes recorded on director elections, say-on-pay, and plan vote.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882796/000117184326004096/0001171843-26-004096-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882796/000117184326004096/f8k_061226.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004096

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer